Sugi Predict

Sugi Predict / Compounds / SCHEMBL15035800

SCHEMBL15035800

SCHEMBL15035800

Cc1ccccc1-c1cc2cnc(Nc3ccc(OC4CCN(C)C4)cc3)nc2n(Cc2cncn2S(=O)(=O)c2ccncc2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 15/20 0.45
▸ SRC P12931 1/20 0.41
▸ RIPK2 O43353 3/20 0.40
▸ NOD2 Q9HC29 3/20 0.40
▸ ACVR1 Q04771 2/20 0.40
▸ CAMK2D Q13557 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034970 0.84 TNK2 (0.48) TNK2SRCRIPK2NOD2ACVR1
SCHEMBL15035671 0.84 TNK2 (0.49) TNK2SRC
SCHEMBL15035851 0.81 TNK2 (0.44) TNK2SRC
SCHEMBL15035028 0.81 TNK2 (0.48) TNK2SRC
SCHEMBL15034913 0.81 TNK2 (0.47) TNK2SRC
SCHEMBL15034808 0.80 TNK2 (0.48) TNK2SRC
SCHEMBL15035747 0.80 TNK2 (0.48) TNK2SRCRIPK2NOD2
SCHEMBL15034859 0.80 TNK2 (0.48) TNK2SRC
SCHEMBL15237011 0.76 TNK2 (0.49) TNK2SRCRIPK2NOD2ACVR1
SCHEMBL14682078 0.76 RIPK2 (0.42) TNK2SRCRIPK2NOD2ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 — — US disclosed
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 — — US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 — — US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK6 TNK2 28/4885SRC 361/4885RIPK2 1162/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 TNK2 7/4885SRC 26/4885RIPK2 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.